

## 14.30 SYMPOSIA FAGGETO HALL

Central European Summer Time (CEST)  
Simultaneous interpreting is NOT FORESEEN



14.30 - 15.00  
**CONTENERE L'ANTIBIOTICO  
RESISTENZA NELLE  
PROCEDURE INTRAVITREALI:  
UNA GUIDA NELLA  
SCELTA DELLE MOLECOLE  
ANTISETTICHE**  
**Moderatore: V. Picardo**  
**Relatori: G. Lo Giudice, A. Piatti, M. Reibaldi**

15.15 - 15.55  
**ANTIBIOTICO VS  
ANTISETTICO: EVIDENZE  
A CONFRONTO PER UNA  
SCELTA APPROPRIATA**

15.15-15.30  
**V. Orfeo**  
Profilassi antibiotica: ragioni, evidenze, controversie  
15.30-15.45  
**R. Mencucci**  
Profilassi antisettica: ragioni, evidenze, controversie  
15.45-15.55  
Discussione

16.10 - 16.40  
**EDEMA MACULARE  
DIABETICO, APPROCCI  
DIAGNOSTICI E TERAPEUTICI**  
**Presidente: C. Costagliola**

16.10 - 16.18  
**D. Bacherini**  
Edema maculare diabetico  
16.18 - 16.26  
**C. Furino**  
Edema maculare diabetico: switch precoce  
16.26 - 16.34  
**F. Chiosi**

Effetto della somministrazione orale di una combinazione fissa di curcumina, artemisinina, bromelina e pepe nero sullo spessore retinico centrale e sulla densità di microaneurismi in pazienti con edema maculare diabetico

16.34 - 16.40 Discussione

17.00 - 17.45  
**RETINAL IMAGING**  
**Moderatori: D. Bacherini, E. Borrelli, V. Capuano, R. Mastropasqua**  
17.00 - 17.06  
**E. Costanzo**

OCT e OCTA:Biomarkers OCT ed OCTA di attività della neovascularizzazione maculare di tipo 1

17.06 - 17.12  
**S. Demirel**  
Pachychoroid neovasculopathy: role for photodynamic therapy (\*)

17.12 - 17.18  
**R. Dolz-Marco**  
High Resolution OCT in macular disease (\*)

17.18 - 17.24  
**C. Iovino**  
Choroidal vascularity index: consigli e accorgimenti

17.24 - 17.30  
**M. Lupidi**  
Risultati nel mondo reale della terapia anti-VEGF nel trattamento naïve della nAMD diagnosticata con Angio OCT: lo studio REVEAL

17.30 -17.36  
**A. Miere**  
Deep learning applications for the diagnosis of retinal atrophy on fundus autofluorescence imaging (\*)

17.36 -17.45  
Discussione

(\*) Traduzione simultanea non prevista

## **Scientific Program: Main Congress - Auditorium Pineta**

Central European Summer Time (CEST)

The meeting will be held in Italian without translation, except where noted

### **THURSDAY 15 APRIL**

13:50	<b>A. Pece, P. Lanzetta</b>	Welcome
13:55	<b>B. Lumbroso</b>	B. Lumbroso's Ouverture

---

### **SESSION I: IMAGING AND RETINAL DIAGNOSTICS**

*Chairmen: L. Pierro, M. Varano*

14:03	<b>G. Staurenghi</b>	Imaging in the management of retinal and choroidal diseases
14:13	<b>G. Lo Giudice</b>	OCT-A: general characteristics
14:21	<b>G. Fasolino</b>	MEK inhibitor retina alteration (MEKAR)
14:29	<b>L. Pierro</b>	OCT-A after endarterectomy for carotid stenosis
14:37	<b>M. Battaglia Parodi</b>	Quantitative OCT-A in AMD-related CNV
14:45	<b>M. Nassisi</b>	Markers OCT in AMD
14:53	<b>E. Borrelli</b>	3D volume rendered OCT-A in type 3 MNV (RAP)
15:01		Discussion

15:10	<b>D. Sarraf</b>	<i>LECTURE: En face OCT: insights into the pathoanatomy of macular disease</i>
-------	------------------	--



---

### **SESSION II: OCT AND OCT-ANGIOGRAPHY (GIAO - GRUPPO ITALIANO ANGIOGRAFIA OCT)**

*Chairmen: F. Bandello, M. Rispoli*

15:25	<b>F. Bandello</b>	The diabetic retinopathy imaging on 360°
15:35	<b>E. Nikolopoulou</b>	OCT-A in epiretinal membranes

15:43	<b>M. Lorusso</b>	OCT during surgery
15:51	<b>I. Zucchiatti</b>	Three-year OCT predictive factors of disease recurrence in eyes with successfully treated myopic CNV
15:59	<b>G. Maione</b>	OCT-A in optic nerve diseases
16:07	<b>A. Pece</b>	The role of Angio OCT in clinical practice
16:15		Discussion
<b>16:25</b>	<b>F. Zancanella</b>	<b>CULTURAL PILL: Eye's reminiscence</b>

### MENTORS AND PROFILING

*Chairman: A. Pece*

16.35	<b>A. Pece</b>	Introduction
	<b>F. Fossataro/G. De Crecchio</b>	
	<b>E. Pilotto/E. Midena</b>	
16.45	<b>A. Pece</b>	Introduction
<b>16:47</b>	<b>L. Yannuzzi</b>	<b>LECTURE: Are there two forms of MEWDS?</b>



### SESSION III: CASES

*Chairman: A. Pece*

17.02	<b>A. Pece</b>	Introduction
17:03	<b>G. Casalino</b>	Case
17:07	<b>A. Papayannis</b>	Case
17:11	<b>E. Interlandi</b>	Case
17:15	<b>D. Veritti</b>	Case
17:19	<b>V. Sarao</b>	Case
17:23	<b>F. Ricci</b>	New therapeutical strategies in AMD
17:31	<b>R. Weitz</b>	Flickering currents and crowded rivers: adaptive optics angiographic translations of OCT-A snapshots



**THURSDAY 15 APRIL - FRIDAY 16 APRIL**

17:46     **A. Loewenstein**

**LECTURE: Adjusting to COVID-19 in 2021 and beyond development in home monitoring including fluid quantification in AMD**



#### **SESSION IV : COVID-2021**

**Chairmen: A. Pece, PG. Neri**

18:01	<b>A. Pece</b>	Introduction
18:03	<b>S. Pece, A. Angelescu, J.M. Dumont, S. Garces, S. Kobayter, P. Rai</b>	Italy  United Kingdom 
		Tackling future pandemics: IE University Project
18:14	<b>C. Azzolini, S. Donati, E. Premi</b>	Use of a dedicated e-health platform in Covid-19 era
18:22	<b>F. Fossataro, A. Pece</b>	Case
18:30	<b>PG. Neri</b>	SARS-CoV-2: an eye business
18:38		Discussion
18:45	<b>G. Guarnaccia</b>	The ESASO reality
18:55		End of the session

## **FRIDAY 16 APRIL**

#### **SESSION V : MACULAR DEGENERATION**

**Chairmen: F. Boscia, P. Lanzetta**

13:30	<b>U. Schmidt-Erfurth</b>	<b>LECTURE: AI-based fluid monitoring and management in exudative macular disease: fluid and function</b>	Italy  United Kingdom 
13:45	<b>A. Pece</b>	The Port Delivery System (PDS) in nAMD	
13:53	<b>P. Lanzetta</b>	Targeting angiopoietin-2 and VEGF in wAMD. The role of Faricimab	
14:03	<b>N. Bressler</b>	<b>LECTURE: Treatment, monitoring &amp; delivery systems for neovascular AMD: current promises and cautions</b>	Italy  United Kingdom 

14:18	<b>F. Boscia</b>	Visual decline after IVT in nAMD
14:26	<b>U. Introini</b>	Non-responders in anti-VEGF treatment in AMD: what to do?
14:34	<b>F. Viola</b>	The impact of coronavirus disease (COVID-19) pandemic on intravitreal injections treatment for macular diseases
14:42	<b>M. Rispoli</b>	Brolucizumab: first experiences
14:50	<b>C. Eandi</b>	Brolucizumab: 1 year later
14:58	<b>M. Varano</b>	Evidence of anti-VEGF use in real life experience in nAMD: the EAGLE study
15:06	<b>G. Querques</b>	Subthreshold laser treatment for RPD secondary to AMD: the PASCAL clinical trial
		 
15:14	<b>A. Pece</b>	Introduction
15:17	<b>N. Yannuzzi</b>	<b>LECTURE: Clinical outcomes of rhegmatogenous retinal detachment treated with pneumatic retinopexy: an IRIS® Registry study</b>
		 

---

## SESSION VI: CENTRAL SEROUS CHORIORETINOPATHY

*Chairmen: M. Nicolò, G. Manzi*

15:32	<b>M.C. Savastano, B. Lumbroso</b>	Neovascularization in CSC by OCT-A
15:40	<b>M. Nicolò</b>	<b>LECTURE: The role of photodynamic therapy in CSC</b>
15:50		<b>RELAX</b>

---

## SESSION VII: DIABETIC RETINOPATHY

*Chairmen: F. Bandello, P. Lanzetta*

16:00	<b>S. Saviano</b>	DME: which is the best therapy?
16:08	<b>R. Lattanzio</b>	Non-responders in anti-VEGF treatment in DME: what to do?
16:16	<b>F. Bandello</b>	Discussion

16:24      **L. M. Jampol**  
 16:39      **S. Bressler**  
 16:54      **P. Lanzetta**

**LECTURE: The DRCR retina network**  

**LECTURE: Proliferative diabetic retinopathy: choosing PRP or anti-VEGF or both**    
 Discussion

### **SESSION VIII: STEROIDS-DME**

**Chairman: T. Avitabile**

17:03      **M. Parravano** Curcumin in hydrophilic carrier and intravitreal dexamethasone in diabetic macular edema  
 17:11      **L. Di Antonio** The inflammatory rational behind DEX implant for medical approach  
 17:19      **M. Lupidi** DEX Implant: first line treatment and early switch  
 17:27      **A. Cutino** Intraocular fluocinolone expansion across the world  
 17:35      **C. Furino** Long term experience with intravitreal fluocinolone acetonide in the real world setting  
 17:43      **P. Airaghi** DME patient management: preventing recurrence preserving vision

**17:51      A. Pece, P. Lanzetta, F. Bandello, N. Bressler, S. Bressler, L. Da Cruz, L. V. Del Priore, L. M. Jampol, A. Loewenstein, P.J. Rosenfeld, D. Sarraf, U. Schmidt-Erfurth, R. Weitz, L. Yannuzzi, N. Yannuzzi**  

**Take home messages**

18:30      End of the session

## **SATURDAY 17 APRIL**

---

### **SESSION IX: THE ROLE OF ORTOPHTHISTS IN CLINICAL PRACTICE**

*Chairmen: S. Gullello, C. Marro*

8:25      **M. Cozzi**                  Multimodal imaging in retinal diseases

8:33      **M. Belotti, E. Maragno**    How to interpret OCT and its use: manual for orthoptist

---

### **SESSION X: MISCELLANEOUS**

*Chairmen: S. Piermarocchi, M. Vadalà*

8:40      **S. Piermarocchi**              Dome-shaped maculopathy

8:50      **E. Midena**                      Radiation (corio)retinopathy: new insights

9:05      **R. Sacconi**                      Macular CNV in geographic atrophy secondary to AMD: is a different entity?

9:13      **P. Milani**                      Active vs inactive myopic CNV

9:21      **D. Allegrini**                      The role of curcuma vehiculated by enterosoma technology in the patient with maculopathy: clinical experience

9:29      **C. Costagliola, M. Filippelli**    Retinal inflammation and AMD: is there a therapeutic “link”?

9:37      **S. Vujosevic**                      Subthreshold micropulse laser

9:45      **P. L. Esposti**                      Treatment with micropulse laser: my personal experience

**9:53      P. J. Rosenfeld**                      *LECTURE: Natural history of treatment naïve, non-exudative macular neovascularization in AMD?*



---

## SESSION XI: LOW VISION

*Chairman: M. Schmid*

10:08	<b>M. Broggini</b>	The low vision in Italy and in the world
10:16	<b>M. Schmid</b>	The role of visual rehabilitation today. New challenges in neurological and non-neurological patients
10:24	<b>A. Pece</b>	Introduction
<b>10:27</b>	<b>G. Trabucchi</b>	<b>CULTURAL PILL: The eye and Holy Scriptures</b>

---

## SESSION XII: TO RESTART



*PRESIDENT: A. Pece*

*SCIENTIFIC BOARD: M.A. Blasi, P. Lanzetta, L. Marino, L. Mosca, S. Vergani*

10:35	<b>A. Pece</b>	Introduction
<b>10:37</b>	<b>S. Rizzo</b>	<b>LECTURE: Macular hole surgery: what's new?</b>
10:52	<b>M.A. Blasi, M.M. Pagliara, M.G. Sammarco</b>	Multimodal imaging in posterior tumors
11:00	<b>L. Marino</b>	Dry eye 2021: therapeutical news
11:08	<b>P. Lanzetta</b>	Laser in diabetic retinopathy
11:16	<b>M. Vadalà, G. Virgili, G. Trifirò, G. Scondotto</b>	Anti-VEGF drugs use and clinical parameters in Southern Italy: ITACA network
11:24	<b>S. Tricarico</b>	Case
11:28	<b>R. Piermarocchi</b>	Case
11:32	<b>A. Pazzaglia</b>	Case
11:36	<b>A. Casanova, A. Consigli, F. Menna, M. Menghini</b>	Case

---

### SESSION XIII: SURGICAL ROUNDS

11:40    **L. Da Cruz**

**LECTURE:** *The causes, management and outcomes of unexplained vitreous hemorrhage*



---

#### 1 ROUND:

**Coordinator:** *M. Codenotti*

11:55

**E. Miserocchi**

Posterior uveitis: when a diagnostic vitrectomy is indicated?

12:05

**F. Patelli, M. Coppola**

Discussion

---

#### 2 ROUND:

**Coordinator:** *M. Romano*

12:25

**T. Micelli Ferrari**

Macular edema and VR traction. Inject or operate?

12:35

**F. Faraldi, D. Tognetto**

Discussion

---

### SESSION XIV: CASES

**Chairmen:** *S. Donati, D. Veritti*

12:55    **S. Donati**              Case

12:59    **F. Martines**              Case

13:03    **V. Starace**              Case

13:07    **M. Battista**              Case

13:11    **M. Brambati**              Case

13:15    **M. Mazzola**              Case

---

## SESSION XV: BIONIC EYE AND FUTURE CHALLENGES

*Panel: P. Lanzetta*

13:19      **L. V. Del Priore**

**LECTURE: Tissue transplantation for AMD: what have we learned?**



13:34      **A.P. Salvetti**

Gene therapy in IRD is here: what's now, what's next?



13:42      **P. Lanzetta**

The future of vitreo-retinal surgery



13:55      **P. Lanzetta, A. Pece**

**Conclusions**

14:00

End of the Congress